Exagen (XGN) Cost of Revenue (2018 - 2026)

Exagen has reported Cost of Revenue for 9 years, with the latest figure at $7.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 11.39% year-over-year to $7.1 million; the trailing twelve-month figure through Mar 2026 stood at $28.5 million (up 23.45% YoY), and the FY2025 full-year result was $27.8 million, up 23.29% from the prior year.
• Cost of Revenue for Q1 2026 stood at $7.1 million, down from $7.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $7.4 million in Q4 2025, with the low at $5.2 million in Q4 2024.
• Historically, Cost of Revenue has averaged $6.2 million across 5 years, with a median of $6.0 million in 2024.
• Annual changes were most pronounced in 2023 — Cost of Revenue fell 10.92% — and 2025, when it surged 43.4%.
• Exagen's Cost of Revenue stood at $6.3 million in 2022, then dropped by 10.92% to $5.6 million in 2023, then slipped by 7.86% to $5.2 million in 2024, then surged by 43.4% to $7.4 million in 2025, then fell by 4.36% to $7.1 million in 2026.
• The last three Cost of Revenue figures came in at $7.1 million (Q1 2026), $7.4 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.